Skip to content

Evaluation of the imaging Software "Syngo DynaPBV Body" for therapy response after transarterial chemoembolisation (TACE).

Evaluation of the imaging Software "Syngo DynaPBV Body" for therapy response after transarterial chemoembolisation (TACE).

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00012604
Enrollment
40
Registered
2017-07-10
Start date
2014-04-30
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: The periprocedural image data as well as the image data of the planning examinations of the patients which are suitable for a "transarterial chemoembolisation" are analyzed by means of an ima

Sponsors

Universitätsmedizin MannheimInstitut für klinische Radiologie und Nuklearmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria for the study was the decision for TACE by the local interdisciplinary tumor board as defining the lesion as not eligible for liver transplantation, surgery, or local ablative treatments in correlation to the recommendations of the "European Association for the Study of the Liver".

Exclusion criteria

Exclusion criteria: Contraindication for DEB TACE were a plasma creatinine level above 2.0 mg/mL, an international normalized ratio (INR) above 2.0, a bilirubin level above 2.0 mg/dl, and a more than five-fold increase in transaminase levels.

Design outcomes

Primary

MeasureTime frame
Comparison of the data collected by the image processing software with the "modified response evaluation criteria in solid tumors". For this purpose, the image data immediately before the intervention and the image data after the intervention for the therapy evaluation are compared with the periprocedural image data.

Countries

Germany

Contacts

Public ContactNils Rathmann

Universitätsklinikum MannheimInstitut für klinische Radiologie und Nuklearmedizin

nils.rathmann@umm.de06213832276

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026